Skin & Psych: Chronic Inflammation and the Emotional Toll

In the inaugural episode of the Skin & Psych Podcast, host Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, sits down with Shanna Miranti, MPAS, PA-C, for a candid discussion on the lived interface between cutaneous disease and mental health. What unfolds is a reflection on the emotional weight that accompanies visible skin disease—for patients and clinicians alike.

Miranti, who has practiced as a PA for more than 2 decades, describes a formative early-career moment when a teenage patient challenged her credibility during a personal flare of hormonally driven acne. Rather than retreating, she reframed the encounter as an opportunity for empathy. “I’ve sat in this hurt with you,” she recalls thinking—an insight that reshaped her approach to patient care. The experience reinforced her belief that effective dermatologic care requires more than diagnostic precision; it requires emotional presence.

Throughout the interview, Miranti returns to the importance of human connection in clinical practice. “If you can take off the clinician mask and be a human being… you will earn their trust for life,” she says. For experienced clinicians, this may resonate as intuitive, yet it is often overshadowed by the cognitive load of managing expanding therapeutic options and evolving guidelines. Younger providers, she notes, may be “so concerned about the overload of information that they don’t stop to take a moment, sit down, listen to the patient.” Her message is not anti-science; rather, it is a call to integrate attunement with evidence-based care.

The psychological toll of chronic inflammatory skin disease emerged as a central theme. Interestingly, Miranti observes that conditions such as psoriasis, atopic dermatitis, acne, and rosacea may generate more sustained distress than many cutaneous malignancies. With skin cancer, “we’ve got a plan. We’re gonna cut it out.” The pathway is defined. In contrast, chronic disease often lacks a clear endpoint. “There’s not always a finish line,” she explains, and patients frequently ask, “Okay, but how long do I have to be on the medicine?” The uncertainty—rather than the diagnosis alone—drives anxiety, frustration, and sometimes hopelessness.

For clinicians accustomed to focusing on morphology and mechanism, this conversation is a reminder that visible disease carries invisible burdens. The delivery of information—tone, posture, pacing—may determine whether patients feel dismissed or understood. As Miranti emphasizes, “The delivery is everything, because if you don’t deliver it in the way that they’re ready to receive it, then they may completely miss the message.”

Ultimately, the episode challenges dermatology providers to balance therapeutic sophistication with relational depth. In an era of expanding biologics and targeted therapies, the most impactful intervention may still begin with empathy.